Amynas

Foundation date

23/12/2019

Sector

#Biotechnology - Therapeutics

Subsector

Amynas’ lead candidate product is a bio-envelope made of electrospun nanofibers designed to promote healthy tissue growth around the implant (anti-inflammatory and anti-scarring) and reduce the infection rate, resulting in fewer re-admission rates for post-surgical complications.

Upcoming events

Latest news

  • Jyseleca®▼ (Filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

    16 hours ago

  • The new Walloon company Cellaïon makes its first closing

    16 hours ago

  • 7 (re)new(ed) strategic partnerships push flanders.bio forward into 2022

    11 hours ago